This dataset provides data for new prescription drugs introduced to market in California with a Wholesale Acquisition Cost (WAC) that exceeds the Medicare Part D specialty drug cost threshold. Prescription drug manufacturers submit information to HCAI within a specified time period after a drug is introduced to market. Key data elements include the National Drug Code (NDC) administered by the FDA, a narrative description of marketing and pricing plans, and WAC, among other information. Manufacturers may withhold information that is not in the public domain. Note that prescription drug manufacturers are able to submit new drug reports for a prior quarter at any time. Therefore, the data set may include additional new drug report(s) from previous quarter(s).

There are two types of New Drug data sets: Monthly and Annual. The Monthly data sets include the data in completed reports submitted by manufacturers for calendar year 2025, as of September 9, 2025. The Annual data sets include data in completed reports submitted by manufacturers for the specified year. The data sets may include reports that do not meet the specified minimum thresholds for reporting.

The program regulations are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/CTRx-Regulations-Text.pdf

The data format and file specifications are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/Format-and-File-Specifications-version-2.0-ada.pdf

DATA NOTES: Due to recent changes in Excel capabilities, it is not recommended that you save these files to .csv format. If you do, when importing back into Excel the leading zeros in the NDC number column will be dropped. If you need to save it into a different format other than .xlsx it must be .txt

DATA UPDATES: Drug manufacturers may submit New Drug reports to HCAI for prescription drugs which were not initially reported when they were introduced to market. CTRx staff update the posted datasets monthly for current year data and as needed for previous years. Please check the 'Data last updated' date on each dataset page to ensure you are viewing the most current data.

This statistic depicts a projection for the total prescription drug revenue worldwide from 2023 to 2030. In 2025, the industry is expected to generate *** trillion U.S. dollars in prescription drug revenue worldwide. Revenues are projected to exceed *** trillion U.S. dollars by 2030. There is an increasing growth, especially, in sales of so-called orphan drugs for the treatment of rare diseases.

The U.S. Prescription Drugs Market size was valued at USD 461.33 USD Billion in 2023 and is projected to reach USD 755.46 USD Billion by 2032, exhibiting a CAGR of 7.3 % during the forecast period. Prescription drugs can only be purchased legally in America after the patient has been prescribed by a licensed pharmacist. It breaks it down into many types, which are Antibiotics, antidepressants, antipsychotics, Painkillers and many more. These drugs are recognized as being very effective in their workings and given in small dosages; the common populace cannot just buy these over the counter. Still, it includes FDA approval, the sources labelling and possible side effects which will have to be observed in the future. They are administered to control diseases that are chronic like high blood pressure, diabetes, depression, and a disease which is likely to be contracted. They have significant roles in the management of health and chronic illness and could potentially act as preventative measures against disease progress, and alleviate symptoms to improve patients’ lives. The benefits of the prescription are that it contains a therapeutic effect, results in minimizing hospital stays and leads to enhanced patient health in the long run. Recent developments include: June 2023: The U.S. FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) manufactured by Boehringer Ingelheim International GmbH to improve blood sugar control in children ten years and older with type 2 diabetes., April 2022: Novartis AG announced the accelerated FDA approval of Vijoice (alpelisib) for treating adult and pediatric patients with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy., March 2021: Astellas Pharma Inc., announced the FDA approval of generic Myrbetriq (mirabegron) tablets for treating neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older.. Key drivers for this market are: Rising Approval of Orphan Drugs by Regulatory Agencies to Fuel Product Demand. Potential restraints include: High Costs of Specialty Prescription Drugs Compared to Over-the-Counter Drugs to Hamper Market Growth. Notable trends are: High Demand for Generic Drugs across the Country.

In 2019, the original drugs segment accounted for nearly ** percent of the Japanese prescription drug market, up from around ** percent in 2008. That year, the drug market share of generics stood at about **** percent.

The Centers for Medicare and Medicaid Services estimate that prescription drug expenditure in the United States will reach around 460 billion U.S. dollars in 2024. This amount includes only retail drug spending, excluding nonretail. Estimations of drug spending can vary by investigating organization. For the U.S., among the most relevant drug spending calculations are provided by CMS, ASPE (Assistant Secretary for Planning and Evaluation), and pharmaceutical market researcher IQVIA. High drug prices in the U.S.The United States is the country with the highest total drug spending, and also with the highest per capita pharmaceuticals spending among developed countries. This is mostly connected to higher drug prices in the United States. For example, the price for the blockbuster drug Humira was almost three times higher in the United States than in Germany in 2017. But whereas in other countries, governments more or less directly control drug prices, the U.S. leaves drug pricing to market competition. As a consequence, the U.S. market is the most profitable for pharmaceutical companies. Where the money is spentNearly half of all Americans have taken at least one prescription medicine within the preceding month. The therapeutic areas where spending is the highest are ‘traditionally’ to be found among antidiabetics, oncologics, autoimmune, and respiratory diseases. Based on number of prescriptions filled, antihypertensives, pain reliever, and mental health drugs are the leading classes.

The prescription delivery service market is evaluated to be sized at US$ 165.4 million in 2024. During the period from 2024 to 2034, the market is expected to progress at a solid clip, registering a CAGR of 5.7%. By 2034, the prescription delivery service market is anticipated to have reached a value of US$ 287.9 million.

Attributes	Details
Prescription Delivery Service Market Value for 2024	US$ 165.4 million
Projected Market Value for 2034	US$ 287.9 million
Value-based CAGR of Market for 2024 to 2034	5.7%

Category-wise Outlook

Attributes	Details
Top Service Type	Prescription Drugs
Market Share (2024)	25.2%

Attributes	Details
Top Delivery Technology	Physical Delivery
Market Share (2024)	32.5%

Country-Wise Analysis

Countries	CAGR (2024 to 2034)
Spain	5.2%
India	6.5%
Italy	5.3%
France	5.3%
Germany	5.1%

The U.S. Pharmaceutical Market size was valued at USD 4.1 billion in 2023 and is projected to reach USD 5.96 billion by 2032, exhibiting a CAGR of 5.48 % during the forecasts period. The U. S Pharmaceutical Industry therefore concerns the manufacturing and marketing of medicines and other therapeutic commodities. This sector is the one able to control, treat or even avoid illnesses and contributes to the improvement of health of the population. They are prescription drugs, over-the-counter drugs as well as biologics. There is an emerging pattern of personalized medicine evident in the increase of genomic and biotechnology plus digital health technologies such as telemedicine, health apps. It is also seeing some growth in areas such as specialty drugs and generics with large amounts being spent on research and development to meet the chronic disease and new health ailments. Global factors are also coming into play in this respect including changes in regulations and problems with pricing. Recent developments include: In December 2023, Pfizer received all regulatory approvals for the acquisition of Seagen. This initiative aims to bring commercial changes in the organization thereby creating a new space, the Pfizer Oncology Division to integrate oncology commercial and R&D operations from both the companies. , In January 2023, Sun Pharma announced the launch of a new drug, SEZABY for treating neonatal seizures in the U.S. This is the first USFDA-approved drug for term and pre-term babies. .

The global prescription medicine market size is projected to reach USD XX million by 2033, exhibiting a CAGR of XX% during the forecast period. The growing prevalence of chronic diseases, aging population, and advancements in drug development are driving market growth. Moreover, the increasing disposable income and healthcare spending in developing countries are contributing to the market expansion. The increasing demand for original brand drugs and generic drugs is segmenting the market. Original brand drugs are patented medicines that are protected from competition, while generic drugs are similar versions of original brand drugs with the same active ingredients. The market is dominated by large pharmaceutical companies such as Pfizer, Roche, Novartis, Johnson & Johnson, and Merck & Co. These companies have a strong portfolio of prescription medicines and invest heavily in research and development. North America holds the largest market share, followed by Europe and Asia Pacific. The growing healthcare expenditure in developed regions and the increasing awareness of healthcare in developing regions are contributing to regional market growth.

In 2024, the Japanese prescription drug market was valued at more than ** trillion Japanese yen, the historically highest value. The market size expanded by nearly four trillion yen throughout the past two decades.

Medicine Market Outlook

The global medicine market size stood at approximately USD 1.4 trillion in 2023 and is projected to reach a staggering USD 2.5 trillion by 2032, growing at a compound annual growth rate (CAGR) of around 6.5%. This robust growth can be attributed to the increasing prevalence of chronic diseases, advancements in medical technology, and the rising geriatric population worldwide. The demand for innovative medicines and treatments continues to fuel the expansion of the market, further strengthened by government initiatives and increasing healthcare expenditure across the globe. The market is poised for substantial growth over the forecast period, driven by these dynamic factors.

A significant growth factor driving the medicine market is the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer. With a rise in lifestyle-related conditions due to sedentary habits, poor diet, and environmental factors, the demand for medications and treatment options has surged. Moreover, the global aging population is expanding rapidly, which further escalates the need for healthcare solutions. This demographic shift creates a substantial market for medicines aimed at managing chronic conditions prevalent among older adults. Additionally, the ongoing development of personalized medicine and precision healthcare, which tailors treatment to individual genetic profiles, is further propelling market growth.

Advancements in medical technology and drug development processes also significantly bolster the medicine market. Innovations in biotechnology, genomics, and nanotechnology have led to the creation of more effective and targeted therapies. Biologics, in particular, have gained prominence due to their potential to treat previously untreatable conditions. Pharmaceutical companies are investing heavily in research and development to bring new and innovative drugs to market, enhancing therapeutic outcomes and patient quality of life. Furthermore, the adoption of digital technologies and artificial intelligence in drug discovery and development processes is accelerating the time-to-market for new medicines, thereby contributing to market expansion.

Another pivotal factor enhancing the growth of the medicine market is the increase in healthcare spending globally. Governments and private organizations are dedicating more resources to improve healthcare infrastructure, making medicines more accessible to the population. The expansion of healthcare insurance coverage and reimbursement policies in many regions has also made medicines more affordable and accessible to a larger audience. In addition, the rise of telemedicine and online pharmacy platforms is changing the way healthcare is delivered, making it easier for patients to obtain necessary medications. These developments in healthcare systems and services are expected to support sustained growth in the medicine market over the coming years.

Regionally, North America continues to dominate the medicine market due to its well-established healthcare infrastructure and high expenditure on research and development. Europe also holds a significant share, driven by an increasing focus on healthcare innovation and chronic disease management. Meanwhile, the Asia Pacific region is expected to witness the highest growth rate, with a CAGR surpassing 8%, fueled by improving healthcare facilities, economic growth, and a rising middle-class population demanding better healthcare services. Emerging markets in Latin America and the Middle East & Africa are also showing promising growth, albeit at a slower pace, as they continue to develop their healthcare systems and address public health challenges.

Product Type Analysis

In the medicine market, product type plays a crucial role in defining the scope and reach of pharmaceutical companies. Prescription medicines hold the largest share of the market due to their essential role in managing and treating both acute and chronic conditions. These medicines are subject to rigorous regulatory standards and require healthcare professionals' authorization for use, ensuring their efficacy and safety. The demand for prescription medications is driven by the rising incidence of chronic diseases and the need for specialized and long-term treatments. Additionally, the emergence of new therapies and drugs targeting specific health conditions continues to bolster the growth of this segment.

Over-the-counter (OTC) medicines, another critical segment, are gaining considerable traction due to their accessibility and affordability. These medicines, available

Graph and download economic data for Producer Price Index by Industry: Pharmacies and Drug Retailers: Retailing of Prescription Drugs (PCU4461104461101) from Jun 2000 to Aug 2025 about prescription drugs, medicines, retail, PPI, industry, inflation, price index, indexes, price, and USA.

In 2024, Market Research Intellect valued the Prescription Drugs Market Report at 1.48 trillion, with expectations to reach 2.25 trillion by 2033 at a CAGR of 5.4%.Understand drivers of market demand, strategic innovations, and the role of top competitors.

The Japan pharmaceutical market, valued at ¥95 billion in 2025, exhibits a moderate growth trajectory with a Compound Annual Growth Rate (CAGR) of 0.92% projected from 2025 to 2033. This relatively low CAGR suggests a mature market characterized by price pressures, stringent regulatory environments, and a focus on innovative therapies. Key drivers include an aging population leading to increased demand for chronic disease treatments, a robust healthcare infrastructure, and ongoing investments in research and development by domestic and international pharmaceutical companies. However, restraints include cost containment measures implemented by the Japanese government, price erosion due to the introduction of generics, and a challenging regulatory approval process. Market segmentation reveals a diverse landscape, with significant contributions from therapeutic areas such as cardiovascular, oncology, and respiratory medications. The prescription drug market, encompassing both branded and generic medications, constitutes a larger portion compared to the Over-The-Counter (OTC) segment. Major players such as Takeda, Astellas, and Daiichi Sankyo dominate the market, leveraging their strong domestic presence and established distribution networks. Future growth will likely be driven by advancements in innovative drug development, particularly in areas like immunotherapy and targeted therapies, as well as increasing adoption of biosimilars. The competitive landscape is intensely competitive, with both established Japanese pharmaceutical companies and multinational corporations vying for market share. Success hinges on strategic partnerships, efficient manufacturing capabilities, and strong regulatory compliance. Furthermore, an increasing focus on personalized medicine and digital health technologies presents both opportunities and challenges for market participants. The market’s evolution will be shaped by government policies aimed at improving access to affordable medications, encouraging innovation, and managing healthcare costs. Companies need to proactively adapt to these shifting dynamics to maintain their market position and achieve sustainable growth. The overall market outlook is one of steady, albeit moderate, expansion, driven by underlying demographic trends and technological advancements within the pharmaceutical industry. Recent developments include: July 2024: Chugai Pharmaceutical Co. Ltd signed an in-licensing agreement with F. Hoffmann-La Roche for in-licensing in vitro PI3Kα inhibitor involisib for the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer with PIK3CA gene mutations. This agreement granted Chugai exclusive development and commercialization rights for involisib in Japan.January 2024: The Japanese Ministry of Health, Labour and Welfare (MHLW) approved the new Eylea 8 mg (aflibercept 8 mg) for neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) based on positive results from clinical trials PULSAR and PHOTON.. Key drivers for this market are: Increasing Burden of Chronic Diseases and the Aging Population, Increasing R&D Activities in the Country. Potential restraints include: Increasing Burden of Chronic Diseases and the Aging Population, Increasing R&D Activities in the Country. Notable trends are: The Branded Drugs Sub-Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

Snapshot img

ePharmacy Market Size 2025-2029

The epharmacy market size is forecast to increase by USD 148.5 billion, at a CAGR of 21.2% between 2024 and 2029.

The market is witnessing significant growth, driven by the increasing availability of high-speed internet services and the subsequent acceptance of online pharmacy services in various regions. This trend is particularly noticeable in newly regulated European states, where consumers are increasingly turning to ePharmacies for the convenience and accessibility they offer. However, the market also faces challenges, with the illegal and counterfeit trading of drugs through ePharmacy platforms posing a significant threat. As regulatory bodies work to combat this issue, ePharmacies must prioritize security measures and transparency to maintain consumer trust and adhere to evolving regulations. To capitalize on the market's potential, companies must focus on providing secure and reliable platforms, ensuring regulatory compliance, and offering competitive pricing and customer service. By addressing these challenges and leveraging the market's growth drivers, ePharmacies can effectively compete in the digital healthcare landscape and meet the evolving needs of consumers.

What will be the Size of the ePharmacy Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market continues to evolve, with dynamic market activities shaping its landscape. Integral components include e-commerce solutions, big data analytics, virtual assistants, order fulfillment, prescription drugs, customer service, health literacy, marketing automation, and AI-powered diagnosis. These elements intertwine, creating a complex web of interconnected services. E-commerce solutions facilitate seamless transactions, while big data analytics enable personalized patient care and predictive modeling. Virtual assistants streamline customer interactions, and order fulfillment ensures timely prescription drug delivery. Prescription drugs remain the core offering, with health literacy initiatives enhancing patient understanding. Marketing automation and AI-powered diagnosis further refine patient care, while medication adherence tools and third-party payer integrations simplify the payment process. Data security measures safeguard sensitive patient information, and referral programs foster customer loyalty. Health monitoring through wearable sensors and telemedicine integration address disease prevention and chronic disease management. Supply chain management, inventory management, and quality control ensure efficient drug distribution. Machine learning and predictive modeling aid in drug discovery and clinical trials. Wellness programs, medication tracking, and insurance claims processing further enrich the ePharmacy experience. Website platforms and virtual consultations provide convenient access to healthcare services, while HIPAA compliance ensures regulatory adherence. Over-the-counter medications, prescription refill reminders, and affiliate marketing expand the market reach. Delivery services, digital therapeutics, personalized medicine, and automated dispensing systems further enhance the ePharmacy experience. The ongoing unfolding of these market activities underscores the continuous evolution of the ePharmacy sector.

How is this ePharmacy Industry segmented?

The epharmacy industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. Product TypeMedicationsHealth and wellness and nutritionPersonal care and essentialsDrug ClassPrescription drugsOver-the-counter drugsDistribution ChannelMobile applicationsOnline platformsEnd-userIndividualsCommercialGeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKAPACChinaIndiaJapanSouth KoreaRest of World (ROW)

By Product Type Insights

The medications segment is estimated to witness significant growth during the forecast period.In the dynamic world of medications, the market is witnessing significant advancements, integrating various technologies to streamline processes and enhance patient care. The prescription verification system ensures accuracy and safety before dispensing, while payment gateways facilitate seamless transactions. Mobile health (mHealth) and telemedicine integration enable remote consultations and monitoring, fostering disease prevention and chronic disease management. Supply chain management, inventory management, and pharmaceutical logistics ensure efficient drug delivery, while clinical trials and drug discovery continue to bring new treatments to market. Machine learning and artificial intelligence power predictive modeling and medication adherence, addressing drug interactions and persona

The global Prescription Drugs Market size was estimated at USD 1.16 trillion in 2024 and is anticipated to grow at a CAGR of 6.94% from 2025 to 2034.

In 2023, the total pharmaceutical market revenue in Italy amounted to approximately **** billion euros. This statistic breaks down this figure, making a distinction between prescription and non-prescription drugs. According to the data, the market of prescription drugs generated a much larger volume of revenue with a value of approximately **** billion euros. The revenue related to non-prescription drugs, instead, was equal to about ***** billion euros.

Pharmacies and drug stores have endured moderate volatility in recent years. Retailers have benefited from a growing and aging population, as older consumers require medication to address chronic ailments, resulting in higher volumes of foot traffic. Similarly, the number of people with private insurance and public funding for Medicare and Medicaid has been on the rise, giving more people access to insurance and supporting demand for prescriptions, pharmacies' largest product segment. These trends, along with consumers increasingly prioritizing their health, have supported revenue gains, causing revenue to grow at an estimated CAGR of 1.1% to $609.6 billion through the end of 2025, including growth of 3.6% that year alone. Pharmacies have endured some challenges during this time, including heightened external competition from big-box stores and online-only pharmacies. With big-box stores offering consumers added convenience, pharmacies have expanded their services to offer some primary care services and grow delivery offerings. Many pharmacies and drug stores have invested in online platforms to service customers who prefer to shop online. The trend of online shopping will intensify in the coming years, and successful drugstores will be positioned to capitalize on the surge in demand. Pharmacies and drug stores have also focused on marketing personal care products, which often have higher prices, to capture additional revenue; however, unfavorable macroeconomic conditions directly harm these product lines because of their less-essential nature and higher access to substitutes. Pharmacies and drug stores will continue to benefit from the ongoing economic recovery, as cooling inflation encourages consumers to make more discretionary purchases like cosmetics and other personal care products. This growth will be fueled by the expansion of store services, including preventive care options and additional front-end offerings. As the number of insured individuals swells, many consumers will continue to fill their prescriptions because of the low out-of-pocket costs. As conditions for the industry improve, so will profit, rising along with revenue. Revenue is expected to climb at a CAGR of 2.6% to $692.0 billion through the end of 2030.

Prescription Drugs Market size is expected to reach USD 2.47 Tn by 2032, from USD 1.34 Tn in 2025, exhibiting a CAGR of 9.1% during the forecast period

The global pharmaceutical retail chain market is experiencing steady growth, projected to maintain a Compound Annual Growth Rate (CAGR) of 5% from 2025 to 2033. While the precise market size for 2025 isn't explicitly stated, considering a typical market size in this sector and applying a logical extrapolation based on a 5% CAGR from a hypothetical 2019 base, we can estimate the 2025 market size to be around $500 billion. This growth is fueled by several key factors. The aging global population and the concomitant rise in chronic diseases necessitate increased pharmaceutical consumption, driving demand. Moreover, the expanding middle class in emerging economies is increasing access to healthcare and pharmaceuticals, further boosting market expansion. Technological advancements, such as online pharmacies and telehealth services, are transforming the retail landscape, improving accessibility and convenience for consumers. Increased government initiatives to improve healthcare infrastructure in developing nations also contribute to the market's growth. However, several challenges temper this growth. Stringent regulatory environments and pricing pressures from governmental bodies and insurance companies can impact profitability. The rise of generic drugs also presents competitive challenges for branded pharmaceutical companies. Furthermore, concerns over prescription drug abuse and counterfeit medications pose significant hurdles to overcome. The market is segmented by various factors including geographical location, product type, and distribution channels. Key players like CVS Health, Walgreens Boots Alliance, and Albertsons dominate the market, particularly in developed economies. The competitive landscape is intensely dynamic with ongoing mergers and acquisitions, expanding market share, and developing new strategies to cater to evolving consumer needs and preferences. The forecast period (2025-2033) will witness significant consolidation among players and a further increase in digitalization across the industry.

The present report entitled “Japan Pharmaceutical Industry & Forecast-Focus on OTC and Prescription Drugs Market†, discuss market size (historical, present and future) of the Japanese pharmaceutical industry and its segments.